المؤلفون: Ricci, Fabrizio, Neumann, Johannes T., Rübsamen, Nicole, Sörensen, Nils A., Ojeda, Francisco, Cataldo, Ivana, Zeller, Tanja, Schäfer, Sarina, Hartikainen, Tau S., Golato, Maria, Palermi, Stefano, Zimarino, Marco, Blankenberg, Stefan, Westermann, Dirk, De Caterina, Raffaele

المصدر: Frontiers in Cardiovascular Medicine. 9

مصطلحات موضوعية: copeptin, coronary artery disease, emergency department, high-sensitivity cardiac troponin, myocardial infarction, Medicin och hälsovetenskap, Klinisk medicin, Kardiologi, Medical and Health Sciences, Clinical Medicine, Cardiac and Cardiovascular Systems

الوصف: Background: The instant, single-sampling rule-out of acute myocardial infarction (AMI) is still an unmet clinical need. We aimed at testing and comparing diagnostic performance and prognostic value of two different single-sampling biomarker strategies for the instant rule-out of AMI. Methods: From the Biomarkers in Acute Cardiac Care (BACC) cohort, we recruited consecutive patients with acute chest pain and suspected AMI presenting to the Emergency Department of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. We compared safety, effectiveness and 12-month incidence of the composite endpoint of all-cause death and myocardial infarction between (i) a single-sampling, dual-marker pathway combining high-sensitivity cardiac troponin I (hs-cTnI) and ultra-sensitive copeptin (us-Cop) at presentation (hs-cTnI ≤ 27 ng/L, us-Cop < 10 pmol/L and low-risk ECG) and (ii) a single-sampling pathway based on one-off hs-cTnI determination at presentation (hs-cTnI < 5 ng/L and low-risk ECG). As a comparator, we used the European Society of Cardiology (ESC) 0/1-h dual-sampling algorithm. Results: We enrolled 1,136 patients (male gender 65%) with median age of 64 years (interquartile range, 51–75). Overall, 228 (20%) patients received a final diagnosis of AMI. The two single-sampling instant rule-out pathways yielded similar negative predictive value (NPV): 97.4% (95%CI: 95.4–98.7) and 98.7% (95%CI: 96.9–99.6) for dual-marker and single hs-cTnI algorithms, respectively (P = 0.11). Both strategies were comparably safe as the ESC 0/1-h dual-sampling algorithm and this was consistent across subgroups of early-comers, low-intermediate risk (GRACE-score < 140) and renal dysfunction. Despite a numerically higher rate of false-negative results, the dual-marker strategy ruled-out a slightly but significantly higher percentage of patients compared with single hs-cTnI determination (37.4% versus 32.9%; P < 0.001). There were no significant between-group differences in 12-month composite outcome. Conclusions: Instant rule-out pathways based on one-off determination of hs-cTnI alone or in combination with us-Cop are comparably safe as the ESC 0/1 h algorithm for the instant rule-out of AMI, yielding similar prognostic information. Instant rule-out strategies are safe alternatives to the ESC 0/1 h algorithm and allow the rapid and effective triage of suspected AMI in patients with low-risk ECG. However, adding copeptin to hs-cTn does not improve the safety of instant rule-out compared with the single rule-out hs-cTn at very low cut-off concentrations.

الوصول الحر: https://lup.lub.lu.se/record/f9f93e0f-96ef-49f8-80c8-27ac96c0acbcTest
http://dx.doi.org/10.3389/fcvm.2022.895421Test

المؤلفون: Catapano, Alberico L., De Caterina, Raffaele, Jukema, J. Wouter, Klempfner, Robert, Landmesser, Ulf, Schiele, François, Sionis, Alessandro, Universitat Autònoma de Barcelona

مصطلحات موضوعية: Acute coronary syndromes, Cardiovascular risk, LDL cholesterol, Lipid-lowering treatments, Myocardial infarction, PCSK9 inhibitors

الوصف: Low-density lipoprotein cholesterol (LDL-C) lowering is key to reduce atherosclerotic disease progression and recurrent events for patients after acute coronary syndrome (ACS). However, LDL-C management for post-ACS patients remains challenging in clinical practice. The ACS EuroPath III project was designed to optimize LDL-C management in post-ACS patients by promoting guideline implementation and translating existing evidence into effective actions. Three surveys targeting cardiologists (n = 555), general practitioners (GPs; n = 445), and patients (n = 662) were conducted in Europe, with the aim of capturing information on patient characteristics and treatment during acute phase, discharge and follow-up. GPs' and patients' opinions on key treatment aspects were also collected. Based on survey results, international experts and clinicians identified areas of improvement and generated prototype solutions. Participants voted to select the most feasible and replicable proposals for co-development and implementation. Five key areas of improvement were identified: (1) inappropriate treatment prescribed at discharge; (2) lack of lipid guidance in the discharge letter; (3) inadequate lipid-lowering therapy (LLT) optimization; (4) gaps in guideline knowledge and lack of referral practices for GPs; (5) patients' concerns about lipid management. Proposed solutions for these focus areas included development of a treatment algorithm for the acute phase, a standardized GP discharge letter, an assessment tool for LLT efficacy at follow-up, an education plan for GPs/patients and a patient engagement discharge kit. The standardized GP discharge letter and treatment algorithm have been selected as the highest priority solutions for development. These initiatives have the potential to improve adherence to guidelines and patient management after ACS. The ACS EuroPath III project was designed to optimize lipid management in post-ACS patients. Following data collection through 3 surveys, 5 key areas for improvement were identified ...

وصف الملف: application/pdf

العلاقة: Clinical Cardiology; Vol. 46 (february 2023), p. 407-415; https://ddd.uab.cat/record/281669Test; urn:10.1002/clc.23988; urn:oai:ddd.uab.cat:281669; urn:pmcid:PMC10106658; urn:pmc-uid:10106658; urn:pmid:36799113; urn:oai:pubmedcentral.nih.gov:10106658; urn:articleid:19328737v46p407

الإتاحة: https://ddd.uab.cat/record/281669Test

المؤلفون: De Caterina, Raffaele, Calabrò, Paolo, Campo, Gianluca, Rossini, Roberta, Giubilato, Simona

المساهمون: De Caterina, Raffaele, Calabrò, Paolo, Campo, Gianluca, Rossini, Roberta, Giubilato, Simona

مصطلحات موضوعية: dual antiplatelet therapy, ticagrelor, myocardial infarction

الوصف: There is uncertainty in cardiologists' attitudes for prolonging dual antiplatelet therapy (DAPT) with ticagrelor 60 mg beyond 12 months in post-myocardial infarction (MI) patients. We aimed at characterizing the Italian cardiologists' perceptions and needs in the management of such patients. Two consecutive questionnaires were proposed between June and November 2021, and compiled by 122 and 87 Cardiologists, respectively. Agreement among cardiologists was defined as either a >70% frequency of concordant responses relative to total respondents or following the Delphi method as developed by the RAND Corporation. An agreement was reached on the indication of ticagrelor as the first choice P2Y(12) inhibitor in MI patients, irrespective of the presentation [ST elevation MI (STEMI), 72%, vs. non-ST elevation MI (NSTEMI), 71%] or the management [invasive vs. conservative (75%)]. A consensus was also achieved on the possibility to consider a patient suitable for long-term DAPT with ticagrelor 60 mg even in case of another P2Y(12) inhibitor used in the first year after the acute event (74, 85%). To define ischemic and bleeding risks, a consensus was reached on the utilization of one or more scores (87, 71%).

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35456184; info:eu-repo/semantics/altIdentifier/wos/WOS:000785174300001; volume:11; issue:8; firstpage:2091-1; lastpage:2091-16; numberofpages:16; journal:JOURNAL OF CLINICAL MEDICINE; https://hdl.handle.net/11392/2520230Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85127879130; https://www.mdpi.com/2077-0383/11/8/2091Test

الإتاحة: https://doi.org/10.3390/jcm11082091Test
https://hdl.handle.net/11392/2520230Test
https://www.mdpi.com/2077-0383/11/8/2091Test

المؤلفون: Pelliccia, Francesco, Zimarino, Marco, Niccoli, Giampaolo, Morrone, Doralisa, De Luca, Giuseppe, Miraldi, Fabio, De Caterina, Raffaele

المصدر: European Heart Journal Open; Sep2023, Vol. 3 Issue 5, p1-11, 11p

مصطلحات موضوعية: PERCUTANEOUS coronary intervention, TRANSLUMINAL angioplasty, MYOCARDIAL infarction, PROGENITOR cells, PLATELET aggregation inhibitors, ENDOTHELIAL cells

مستخلص: Percutaneous coronary intervention (PCI) has evolved significantly over the past four decades. Since its inception, in-stent restenosis (ISR)—the progressive reduction in vessel lumen diameter after PCI—has emerged as the main complication of the procedure. Although the incidence of ISR has reduced from 30% at 6 months with bare-metal stents to 7% at 4 years with drug-eluting stents (DESs), its occurrence is relevant in absolute terms because of the dimensions of the population treated with PCI. The aim of this review is to summarize the emerging understanding of the biological pathways that underlie ISR. In-stent restenosis is associated with several factors, including patient-related, genetic, anatomic, stent, lesion, and procedural characteristics. Regardless of associated factors, there are common pathophysiological pathways involving molecular phenomena triggered by the mechanical trauma caused by PCI. Such biological pathways are responses to the denudation of the intima during balloon angioplasty and involve inflammation, hypersensitivity reactions, and stem cell mobilization particularly of endothelial progenitor cells (EPCs). The results of these processes are either vessel wall healing or neointimal hyperplasia and/or neo-atherosclerosis. Unravelling the key molecular and signal pathways involved in ISR is crucial to identify appropriate therapeutic strategies aimed at abolishing the 'Achille's heel' of PCI. In this regard, we discuss novel approaches to prevent DES restenosis. Indeed, available evidence suggests that EPC-capturing stents promote rapid stent re-endothelization, which, in turn, has the potential to decrease the risk of stent thrombosis and allow the use of a shorter-duration dual antiplatelet therapy. Graphical Abstract [ABSTRACT FROM AUTHOR]

: Copyright of European Heart Journal Open is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: De Caterina, Raffaele, Patti, Giuseppe, Westerbergh, Johan, Horowitz, John, Ezekowitz, Justin A, Lewis, Basil S, Lopes, Renato D, McMurray, John J V, Atar, Dan, Bahit, M Cecilia, Keltai, Matyas, López-Sendón, José L, Ruzyllo, Witold, Granger, Christopher B, Alexander, John H, Wallentin, Lars, 1943

المصدر: European Heart Journal - Cardiovascular Pharmacotherapy. 8(3):227-235

مصطلحات موضوعية: Atrial fibrillation, Death, Diabetes, Insulin, Myocardial infarction, Stroke

الوصف: AIMS: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial.METHODS AND RESULTS: Patients with AF and increased stroke risk randomized to apixaban vs. warfarin were classified according to diabetes status: no diabetes; diabetes on no diabetes medications; diabetes on non-insulin antidiabetic drugs only; or insulin-treated. The associations between such patient subgroups and stroke/systemic embolism (SE), myocardial infarction (MI), and CV death were examined by Cox proportional hazard regression, both unadjusted and adjusted for other prognostic variables. Patients with diabetes were younger and had a higher body mass index. Median CHA2DS2VASc score was 4.0 in patients with diabetes and 3.0 in patients without diabetes. We found no significant difference in stroke/SE incidence across patient subgroups. Compared with no diabetes, only insulin-treated diabetes was significantly associated with higher risk. When adjusted for clinical variables, compared with no diabetes, the hazard ratios (HRs) for MI (95% confidence intervals) were for diabetes on no medication: 1.15 (0.62-2.14); for diabetes on non-insulin antidiabetic drugs: 1.32 (0.90-1.94); for insulin-treated diabetes: 2.34 (1.43-3.82); interaction P = 0.008. HRs for CV death were for diabetes on no medication: 1.19 (0.86-166); for diabetes on non-insulin antidiabetic drugs: 1.12 (0.88-1.42); for insulin-treated diabetes 1.85 (1.36-2.53), interaction P = 0.001.CONCLUSION: In anticoagulated patients with AF, a higher risk of MI and CV death is largely confined to diabetes treated with insulin.

وصف الملف: print

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-430985Test

المؤلفون: Madonna, Rosalinda, Petrov, Lyubomir, Teberino, Maria Anna, MANZOLI, Lamberto, Karam, Jean Pierre, Renna, Francesca Vera, Ferdinandy, Peter, Montero Menei, Claudia N., Ylä Herttuala, Seppo, De Caterina, Raffaele

المساهمون: Madonna, Rosalinda, Petrov, Lyubomir, Teberino, Maria Anna, Manzoli, Lamberto, Karam, Jean Pierre, Renna, Francesca Vera, Ferdinandy, Peter, Montero Menei, Claudia N., Ylä Herttuala, Seppo, De Caterina, Raffaele

مصطلحات موضوعية: Adipose tissue-derived mesenchymal stromal cell, Microsphere, Myocardial infarction, Adipose Tissue, Animal, Cells, Cultured, Male, Mice, Inbred C57BL, Vascular Endothelial Growth Factor A, Mesenchymal Stem Cell Transplantation, Physiology

الوصف: Rationale Engraftment and survival of transplanted stem or stromal cells in the microenvironment of host tissues may be improved by combining such cells with scaffolds to delay apoptosis and enhance regenerative properties.Aims We examined whether poly(lactic-co-glycolic acid) pharmacologically active microcarriers (PAMs) releasing vascular endothelial growth factor (VEGF) enhance survival, differentiation, and angiogenesis of adipose tissue-mesenchymal stromal cells (AT-MSCs). We analysed the efficacy of transplanted AT-MSCs conjugated with PAMs in a murine model of acute myocardial infarction (AMI).Methods and results We used fibronectin-coated (empty) PAMs or VEGF-releasing PAMs covered with murine AT-MSCs. Twelve-month-old C57 mice underwent coronary artery ligation to induce AMI, and were randomized into five treatment groups: AMI control (saline 20 mu L, n = 7), AMI followed by intramyocardial injection with AT-MSCs (2.5 x 10(5) cells/20 mu L, n = 5), or concentrated medium (CM) from AT-MSCs (20 mu L, n = 8), or AT-MSCs (2.5 x 10(5) cells/20 mu L) conjugated with empty PAMs (n = 7), or VEGF-releasing PAMs (n = 8). Sham-operated mice (n = 7) were used as controls. VEGF-releasing PAMs increased proliferation and angiogenic potential of AT-MSCs, but did not impact their osteogenic or adipogenic differentiation. AT-MSCs conjugated with VEGF-releasing PAMs inhibited apoptosis, decreased fibrosis, increased arteriogenesis and the number of cardiac-resident Ki-67 positive cells, and improved myocardial fractional shortening compared with AT-MSCs alone when transplanted into the infarcted hearts of C57 mice. With the exception of fractional shortening, all such effects of AT-MSCs conjugated with VEGF-PAMs were paralleled by the injection of CM.Conclusions AT-MSCs conjugated with VEGF-releasing PAMs exert paracrine effects that may have therapeutic applications.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/26187727; info:eu-repo/semantics/altIdentifier/wos/WOS:000362851400005; volume:108; issue:1; firstpage:39; lastpage:49; numberofpages:11; journal:CARDIOVASCULAR RESEARCH; http://hdl.handle.net/11392/2360362Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84943368819; https://academic.oup.com/cardiovascres/article/108/1/39/265958Test

الإتاحة: https://doi.org/10.1093/cvr/cvv197Test
http://hdl.handle.net/11392/2360362Test
https://academic.oup.com/cardiovascres/article/108/1/39/265958Test

المؤلفون: Marco Zimarino, CORAZZINI, ALESSANDRO, RICCI, FABRIZIO, DI NICOLA, MARTA, DE CATERINA, Raffaele

المساهمون: Marco, Zimarino, Corazzini, Alessandro, Ricci, Fabrizio, DI NICOLA, Marta, DE CATERINA, Raffaele

مصطلحات موضوعية: CI, DDS, DES, MI, PCI, RCT, RR, SDS, TVR, confidence interval, coronary bifurcation, double drug-eluting stent strategy, drug-eluting stent thrombosi, drug-eluting stent(s), myocardial infarction, nROS, nonrandomized, observational study, percutaneous coronary intervention, randomized, controlled trial, relative risk, single drug-eluting stent strategy, target vessel revascularization

الوصف: OBJECTIVES: This study sought to hypothesize that the higher risk of myocardial infarction (MI) documented after a routine double drug-eluting stent (DES) strategy (DDS) compared with a single DES strategy (SDS) with provisional stenting in percutaneous coronary interventions (PCI) of bifurcation lesions is driven by an increased rate of DES thrombosis. BACKGROUND: The results of currently available randomized, controlled trials (RCTs) were inconclusive in the choice between SDS and DDS. Meta-analyses have shown an increased risk of MI in the DDS group, without identifying the underlying mechanism(s). METHODS: We performed a meta-analysis of 12 major (>100 patients) studies of bifurcation DES PCI: 5 RCTs and 7 nonrandomized observational studies, for a total of 6,961 patients. Random-effects models were used to calculate summary risk ratios (RRs). As a primary endpoint, we assessed the RRs and 95% confidence intervals (CIs) of definite DES thrombosis; death, MI, and target vessel revascularization (TVR) were evaluated as secondary endpoints. RESULTS: Compared with SDS, DDS had an increased risk of DES thrombosis (RR: 2.31; 95% CI: 1.33 to 4.03) and MI (RR: 1.86; 95% CI: 1.34 to 2.60). Mortality (RR: 1.18; 95% CI: 0.85 to 1.65) and TVR (RR: 1.02; 95% CI: 0.80 to 1.30) were similar. The RRs of MI and DES thrombosis were associated (p = 0.040). CONCLUSIONS: In PCI of coronary bifurcations, SDS should be the preferred approach, as DDS is associated with an increased risk of MI, likely driven by DES thrombosis.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23769650; info:eu-repo/semantics/altIdentifier/wos/WOS:000322129400009; volume:6; issue:7; firstpage:687; lastpage:695; numberofpages:9; journal:JACC: CARDIOVASCULAR INTERVENTIONS; http://hdl.handle.net/11564/444485Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84880271031; https://www.sciencedirect.com/science/article/pii/S193687981300808XTest

الإتاحة: https://doi.org/10.1016/j.jcin.2013.03.012Test
http://hdl.handle.net/11564/444485Test
https://www.sciencedirect.com/science/article/pii/S193687981300808XTest

المؤلفون: Lopez-Ayala, Pedro¹ (AUTHOR), De Caterina, Raffaele^2,3 (AUTHOR), Mueller, Christian¹ (AUTHOR) christian.mueller@usb.ch

المصدر: Vascular Pharmacology. Jun2024, Vol. 155, pN.PAG-N.PAG. 1p.

مصطلحات موضوعية: *MYOCARDIAL infarction, *DEFINITIONS

المؤلفون: Patti, Giuseppe, Sticchi, Alessandro, Pasceri, Vincenzo, Ricci, Fabrizio, Renda, Giulia, Hamrefors, Viktor, Melander, Olle, Sutton, Richard, Engström, Gunnar, De Caterina, Raffaele, Fedorowski, Artur

المساهمون: Patti, Giuseppe, Sticchi, Alessandro, Pasceri, Vincenzo, Ricci, Fabrizio, Renda, Giulia, Hamrefors, Viktor, Melander, Olle, Sutton, Richard, Engström, Gunnar, De Caterina, Raffaele, Fedorowski, Artur

مصطلحات موضوعية: CHA2DS2-VASc score, cardiovascular disease risk, death, diabete, myocardial infarction, predictive value, stroke

الوصف: Risk factors included in the cardiovascular (CHA2 DS2 -VASc) score, currently used for atrial fibrillation (AF), may predispose to cardiovascular events whether or not AF is present. The aim was to explore the predictive role of CHA2 DS2 -VASc score on cardiovascular outcomes in diabetic patients without AF.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000490279900015; firstpage:e3145; journal:DIABETES/METABOLISM RESEARCH AND REVIEWS; http://hdl.handle.net/11579/108215Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85068393479

الإتاحة: https://doi.org/10.1002/dmrr.3145Test
http://hdl.handle.net/11579/108215Test

المؤلفون: Thygesen, Kristian, Alpert, Joseph S., Jaffe, Allan S., Chaitman, Bernard R., Bax, Jeroen J., Morrow, David A., White, Harvey D., Mickley, Hans, Crea, Filippo, Van De Werf, Frans, Bucciarelli-Ducci, Chiara, Katus, Hugo A., Pinto, Fausto J., Antman, Elliott M., Hamm, Christian W., De Caterina, Raffaele, Januzzi, James L., Apple, Fred S., Garcia, Maria Angeles Alonso, Underwood, S. Richard, Canty, John M., Lyon, Alexander R., Devereaux, P. J., Zamorano, Jose Luis, Lindahl, Bertil, Weintraub, William S., Newby, L. Kristin, Virmani, Renu, Vranckx, Pascal, Cutlip, Don, Gibbons, Raymond J., Smith, Sidney C., Atar, Dan, Luepker, Russell V., Robertson, Rose Marie, Bonow, Robert O., Steg, P. Gabriel, O’Gara, Patrick T., Fox, Keith A. A., Hasdai, David, Aboyans, Victor, Achenbach, Stephan, Agewall, Stefan, Alexander, Thomas, Avezum, Alvaro, Barbato, Emanuele, Bassand, Jean-Pierre, Bates, Eric, Bittl, John A., Breithardt, Güenter, Bueno, Héctor, Bugiardini, Raffaele, Cohen, Mauricio G., Dangas, George, De Lemos, James A., Delgado, Victoria, Filippatos, Gerasimos, Fry, Edward, Granger, Christopher B., Halvorsen, Sigrun, Hlatky, Mark A., Ibanez, Borja, James, Stefan, Kastrati, Adnan, Leclercq, Christophe, Mahaffey, Kenneth W., Mehta, Laxmi, Müller, Christian, Patrono, Carlo, Piepoli, Massimo Francesco, Piñeiro, Daniel, Roffi, Marco, Rubboli, Andrea, Sharma, Samin, Simpson, Iain A., Tendera, Michael, Valgimigli, Marco, Van Der Wal, Allard C., Windecker, Stephan

المساهمون: Thygesen, Kristian*, Alpert, Joseph S., Jaffe, Allan S., Chaitman, Bernard R., Bax, Jeroen J., Morrow, David A., White, Harvey D., Mickley, Han, Crea, Filippo, Van De Werf, Fran, Bucciarelli-Ducci, Chiara, Katus, Hugo A., Pinto, Fausto J., Antman, Elliott M., Hamm, Christian W., De Caterina, Raffaele, Januzzi, James L., Apple, Fred S., Garcia, Maria Angeles Alonso, Underwood, S. Richard, Canty, John M., Lyon, Alexander R., Devereaux, P.J., Zamorano, Jose Lui, Lindahl, Bertil, Weintraub, William S., Newby, L. Kristin, Virmani, Renu, Vranckx, Pascal, Cutlip, Don, Gibbons, Raymond J., Smith, Sidney C., Atar, Dan, Luepker, Russell V., Robertson, Rose Marie, Bonow, Robert O., Steg, P. Gabriel, O’Gara, Patrick T., Fox, Keith A. A., Hasdai, David, Aboyans, Victor, Achenbach, Stephan, Agewall, Stefan, Alexander, Thoma, Avezum, Alvaro, Barbato, Emanuele, Bassand, Jean-Pierre, Bates, Eric, Bittl, John A., Breithardt, Güenter, Bueno, Héctor, Bugiardini, Raffaele, Cohen, Mauricio G., Dangas, George, De Lemos, James A., Delgado, Victoria, Filippatos, Gerasimo, Fry, Edward, Granger, Christopher B., Halvorsen, Sigrun, Hlatky, Mark A., Ibanez, Borja, James, Stefan, Kastrati, Adnan, Leclercq, Christophe, Mahaffey, Kenneth W., Mehta, Laxmi, Müller, Christian, Patrono, Carlo, Piepoli, Massimo Francesco, Piñeiro, Daniel, Roffi, Marco, Rubboli, Andrea, Sharma, Samin, Simpson, Iain A., Tendera, Michael, Valgimigli, Marco, Van Der Wal, Allard C., Windecker, Stephan

مصطلحات موضوعية: Cardiac procedural myocardial injury, Cardiac troponin, Expert Consensus Document, High sensitivity cardiac troponin, Myocardial infarction, Myocardial infarction with non-obstructive coronary arteries (MINOCA), Myocardial injury, Prior myocardial infarction, Re-infarction, Recurrent myocardial infarction, Silent myocardial infarction, Takotsubo syndrome, Type 1 MI, Type 2 MI, Type 3 MI, Type 4a MI, Type 4b MI, Type 4c MI, Type 5 MI, Cardiology and Cardiovascular Medicine

الوصف: N/A

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30165617; info:eu-repo/semantics/altIdentifier/wos/WOS:000459338100008; volume:40; issue:3; firstpage:237; lastpage:269; numberofpages:33; journal:EUROPEAN HEART JOURNAL; http://hdl.handle.net/11585/682920Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85058158540; http://eurheartj.oxfordjournals.orgTest/

الإتاحة: https://doi.org/10.1093/eurheartj/ehy462Test
http://hdl.handle.net/11585/682920Test
http://eurheartj.oxfordjournals.orgTest/